Visit Natera.com

Investor Relations

Set Up Alert

About Natera

Natera™ is a global leader in cell-free DNA (cfDNA) testing with a focus on women’s health, oncology, and organ health.

 

Our cutting-edge cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and AI, allowing detection down to a single molecule in a tube of blood. We’ve leveraged this platform to develop the most accurate non-invasive prenatal test on the market (Panorama™), the first tumor-specific assay for truly individualized cancer care (Signatera™), and best-in-class rejection assessment for kidney transplantation (Prospera™), among other transformative cfDNA tests.

 

Natera has performed more than 3 million cfDNA tests in its laboratories, more than any other, studied over 1.3 million patients and has been published in over 50 peer reviewed publications.

 
Learn More
 
Natera San Carlos

Stock Information

Change
Volume
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Learn More

Recent News

June 4, 2021
Natera Announces New Prospera™ Data at the ATC 2021 Virtual Connect Conference
AUSTIN, Texas , June 4, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it will present new data on its latest scientific innovations in cfDNA testing at the American Transplant Congress' (ATC) 2021 Virtual Connect,
More
May 28, 2021
Natera Responds to Meritless Lawsuit and Files False Advertising Claim Against Guardant for Misleading Oncologists
AUSTIN, Texas , May 28, 2021 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it has been sued by Guardant Health, in an attempt to stop Natera from exposing Guardant Reveal's™ true test performance and the differences
More
May 26, 2021
New Signatera™ Data in Multiple Myeloma, Colorectal Cancer and Ovarian Cancer Highlights Clinical Utility of MRD in Real-World Settings
AUSTIN, Texas , May 26, 2021 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new clinical data on its personalized and tumor-informed molecular residual disease (MRD) assay, Signatera, at the 2021 American Society
More
May 20, 2021
Natera to Present Clinical Data from Largest Prospective MRD-Guided Trial in Colorectal Cancer at the 2021 ASCO Annual Meeting
Initial analysis of 400 patients from CIRCULATE-Japan study showcases Signatera's market-leading performance with over 95% pre-surgical detection and 92% relapse sensitivity AUSTIN, Texas , May 20, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA
More
May 6, 2021
Natera Reports First Quarter 2021 Financial Results
AUSTIN, Texas , May 6, 2021 /PRNewswire/ --  Natera, Inc. (NASDAQ:  NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the first quarter ended March 31, 2021 and provided an update on recent business progress and financial outlook.
More
Read More

Upcoming Events

More events are coming soon.


Learn More

Past events

Read More

Recent Presentations

Learn More
The information provided in this area of the website is maintained by a third-party service. Natera is not responsible for the accuracy, currency or completeness of the information contained herein.

Data Provided by Refinitiv. Minimum 15 minutes delayed.